Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.

Leukemia - 1 May 2009

Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P

Abstract excerpt

Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm characterized by the FIP1L1-PDGFRA fusion gene, variant PDGFRA fusions or other genetic lesions. Most FIP1L1-PDGFRA positive patients enjoy durable and complete molecular responses to low-dose imatinib (Glivec/Gleevec). However, resistance mediated by a T674I mutation in the ATP-binding pocket of PDGFRA has been reported in advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hypereosinophilic Syndrome

Share to mRNA Cleavage and Polyadenylation Factors

Share to Precursor Cells, B-Lymphoid

Share to Receptors, Vascular Endothelial Growth Factor

Share to Salvage Therapy

Share to Sorafenib

Source

Identifiers

PMID: 19212337
DOI: 10.1038/leu.2009.2

Genes

PDGFRA
CEL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.PMID 19212337Read ↗

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.Semantic proximity Read ↗

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutationSemantic proximity Read ↗

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.Semantic proximity Read ↗

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.Semantic proximity Read ↗

The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and managementSemantic proximity Read ↗

Atypical Phenotype and Treatment Response Pattern in a Patient with FIP1L1-PDGFRα Mutation.Semantic proximity Read ↗

[FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].Semantic proximity Read ↗

Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.Semantic proximity Read ↗

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.Semantic proximity Read ↗

Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy.Semantic proximity Read ↗

The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.Semantic proximity Read ↗

Imatinib for the treatment of hypereosinophilic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.